valoctocogene roxaparvovec sold brand name roctavian gene therapy used treatment hemophilia developed biomarin valoctocogene roxaparvovec made virus modified contain gene factor viii lacking people hemophilia adenoassociated virus vectorbased gene given intravenous common side effects include increased levels liver enzymes alanine aminotransferase aspartate aminotransferase signs possible liver problems increased levels enzyme lactate dehydrogenase sign possible tissue damage nausea feeling sick valoctocogene roxaparvovec approved medical use european union august united states june european union valoctocogene roxaparvovec indicated treatment severe hemophilia congenital factor viii deficiency adults without history factor viii inhibitors without detectable antibodies adenoassociated virus serotype united states valoctocogene roxaparvovec indicated treatment adults severe hemophilia congenital factor viii deficiency factor viii activity iudl without preexisting antibodies adenoassociated virus serotype detected fdaapproved valoctocogene roxaparvovec gene therapy uses adenoassociated virus codes human factor viii together human liverspecific promoter encourages translation hepatocytes liver endothelial sinusoidal cells factor viii ordinarily us food drug administration fda granted valoctocogene roxaparvovec orphan drug status breakthrough therapy designation however august biomarin received complete response letter fda indicating biologics license application would made valoctocogene roxaparvovec first gene therapy approved bleeding disorder would regulator concerned differences results phase iii trials phase iii trial dissimilar regard durability latter suggesting protective effect valoctocogene roxaparvovec wore approx safety effectiveness valoctocogene roxaparvovec evaluated multinational study adult men years age severe hemophilia previously treated factor viii replacement effectiveness established based results cohort participants followed least years valoctocogene roxaparvovec following infusion mean annualized bleeding rate decreased bleeds per year baseline bleeds per majority participants received valoctocogene roxaparvovec received corticosteroids suppress immune system gene therapy effective fda granted application valoctocogene roxaparvovec orphan drug breakthrough therapy regenerative medicine advanced therapy priority review fda granted approval roctavian biomarin pharmaceutical june committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting conditional marketing authorization medicinal product roctavian intended treatment severe haemophilia roctavian advanced therapy medicinal product chmp positive opinion based assessment committee advanced applicant medicinal product biomarin international valoctocogene roxaparvovec approved medical use european union august june us fda approved valoctocogene roxaparvovec treatment adults severe hemophilia without preexisting antibodies adenoassociated virus serotype detected fdaapproved drug article relating blood blood forming organs stub help wikipedia expanding httpsenwikipediaorgwikivaloctocogeneroxaparvovec